Genelux Q3 EPS Lifted by Brookline Capital Management

Genelux Co. (NASDAQ:GNLX) – Analysts at Brookline Capital Management upped their Q3 2025 earnings per share estimates for Genelux in a report released on Tuesday, May 6th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.21). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s FY2025 earnings at ($0.83) EPS.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Genelux in a report on Monday, March 31st. Benchmark dropped their price target on shares of Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a research note on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $17.75.

Genelux Stock Up 3.9 %

Shares of Genelux stock opened at $2.96 on Friday. The business has a 50 day moving average price of $2.96 and a 200-day moving average price of $3.11. The company has a market cap of $111.70 million, a PE ratio of -3.12 and a beta of -0.33. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of Genelux during the 4th quarter valued at $25,000. Advisor Resource Council purchased a new position in Genelux in the first quarter worth about $34,000. Apollon Wealth Management LLC grew its stake in shares of Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Genelux during the 4th quarter valued at about $41,000. Finally, Liberty Wealth Management LLC bought a new position in shares of Genelux in the 1st quarter worth approximately $45,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.